| Recruiting | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T- NCT07137416 | National Cancer Institute (NCI) | Phase 1 |
| Not Yet Recruiting | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones NCT06982222 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Met NCT06860815 | City of Hope Medical Center | Phase 2 |
| Recruiting | [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic NCT06502691 | University of Washington | Phase 1 / Phase 2 |
| Recruiting | Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, NCT07158021 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Living Well With Advanced Breast Cancer NCT07227038 | Ohio State University Comprehensive Cancer Center | — |
| Not Yet Recruiting | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer NCT04529044 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non- NCT06910761 | City of Hope Medical Center | Phase 2 |
| Recruiting | Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis NCT06500481 | NRG Oncology | Phase 3 |
| Recruiting | Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast C NCT06518057 | University of Washington | Phase 2 |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Completed | MBC Physical Activity Study NCT06500858 | Thomas Jefferson University | N/A |
| Recruiting | A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer NCT06557148 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Rece NCT06260033 | City of Hope Medical Center | Phase 2 |
| Terminated | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improvi NCT06315296 | Thomas Jefferson University | N/A |
| Suspended | Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With NCT05751668 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Withdrawn | A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer NCT06145399 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |
| Recruiting | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Ad NCT05372640 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or L NCT05746325 | Mayo Clinic | N/A |
| Active Not Recruiting | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable a NCT04616248 | University of Southern California | Phase 1 |
| Recruiting | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brai NCT05376878 | City of Hope Medical Center | Phase 4 |
| Withdrawn | Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastati NCT05533320 | City of Hope Medical Center | N/A |
| Recruiting | A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Trea NCT05534438 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy NCT05315687 | Emory University | Phase 2 |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Can NCT05215769 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast Cancer NCT06206239 | Thomas Jefferson University | — |
| Active Not Recruiting | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fa NCT04673448 | University of Washington | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and P NCT04108858 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer NCT04498520 | Pamela Munster | Phase 1 |
| Withdrawn | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positiv NCT04756505 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Completed | Apollo Device for Metastatic Breast Cancer (MBC) NCT04983342 | Margaret Quinn Rosenzweig | N/A |
| Withdrawn | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic NCT04418219 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Terminated | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors NCT04541225 | Nuvation Bio Inc. | Phase 1 |
| Suspended | Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring NCT04906369 | Mayo Clinic | — |
| Withdrawn | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer NCT04351230 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study NCT04316117 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Ca NCT04090567 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors NCT04526587 | Roswell Park Cancer Institute | — |
| Active Not Recruiting | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cance NCT03939897 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Recep NCT04585724 | Emory University | Phase 1 |
| Unknown | Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breas NCT04262518 | Outcomes4Me | N/A |
| Suspended | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer NCT04120246 | Veana Therapeutics | Phase 1 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Recruiting | Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. NCT04305834 | City of Hope Medical Center | Phase 2 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Suspended | Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer NCT03737695 | Mayo Clinic | — |
| Completed | Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Can NCT03207529 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Can NCT04256941 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients NCT03924466 | Universitair Ziekenhuis Brussel | Phase 2 |
| Recruiting | Intravital Microscopy in Human Solid Tumors NCT03823144 | Mayo Clinic | N/A |
| Withdrawn | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer NCT03803761 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis NCT03691493 | Emory University | Phase 2 |
| Completed | Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Communi NCT04297384 | Roswell Park Cancer Institute | N/A |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Brea NCT03524170 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741 | Mayo Clinic | Phase 1 |
| Completed | Metastatic Breast Carcinoma and Women Sexual Quality of Life NCT03408769 | Institut de Cancérologie de Lorraine | — |
| Terminated | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treatin NCT03101748 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positi NCT03281902 | Mayo Clinic | — |
| Active Not Recruiting | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Canc NCT02849496 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | The p53 Breast Cancer Trial NCT02965950 | Haukeland University Hospital | Phase 2 |
| Active Not Recruiting | Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Met NCT02778685 | City of Hope Medical Center | Phase 2 |
| Completed | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or B NCT02595905 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer NCT02474173 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival NCT02364557 | NRG Oncology | Phase 2 / Phase 3 |
| Recruiting | Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Brea NCT06217874 | Mayo Clinic | — |
| Active Not Recruiting | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Can NCT02115282 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer NCT01463072 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer NCT01351909 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer NCT01174121 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer NCT01149083 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Rec NCT01142401 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer NCT00429182 | M.D. Anderson Cancer Center | Phase 2 |